(NASDAQ: NRIX) Nurix Therapeutics's forecast annual revenue growth rate of 11.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.15%.
Nurix Therapeutics's revenue in 2026 is $83,980,000.On average, 19 Wall Street analysts forecast NRIX's revenue for 2026 to be $5,760,339,945, with the lowest NRIX revenue forecast at $0, and the highest NRIX revenue forecast at $10,258,590,447. On average, 15 Wall Street analysts forecast NRIX's revenue for 2027 to be $6,921,643,237, with the lowest NRIX revenue forecast at $0, and the highest NRIX revenue forecast at $22,922,678,945.
In 2028, NRIX is forecast to generate $13,102,199,729 in revenue, with the lowest revenue forecast at $866,760,905 and the highest revenue forecast at $37,346,411,378.